Home

The Cuban Center for State Control of Medicines, Equipment and Medical Devices approved the phase I/II clinical trial to evaluate the safety and immunogenicity of the vaccine candidate Mambisa -intranasal- and the Abdala vaccine -intramuscular-, a study to boost immunity in convalescents of COVID-19.

The efficacy of the Soberana 02 vaccine candidate in its three-dose schedule together with Soberana Plus is 91.2%, which exceeds the World Health Organization (WHO) requirements for a vaccine candidate against COVID-19 to become a vaccine, which is 50%.

Design, obtaining and preclinical assessment of Cuban anti-Covid Soberana 02 vaccine candidate reached the headlines of the US magazine ACS Chemical Biology, paving the way for other antiviral vaccines.